Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB‐552 in mouse models
- 20 July 2014
- journal article
- research article
- Published by Wiley in Journal of Peptide Science
- Vol. 20 (11) , 850-859
Abstract
Accumulation of the COMMD1 protein as a druggable pharmacology event to target cancer cells has not been evaluated so far in cancer animal models. We have previously demonstrated that a second‐generation peptide, with cell‐penetrating capacity, termed CIGB‐552, was able to induce apoptosis mediated by stabilization of COMMD1. Here, we explore the antitumor effect by subcutaneous administration of CIGB‐552 in a therapeutic schedule. Outstandingly, a significant delay of tumor growth was observed at 0.2 and 0.7 mg/kg (p < 0.01) or 1.4 mg/kg (p < 0.001) after CIGB‐552 administration in both syngeneic murine tumors and patient‐derived xenograft models. Furthermore, we evidenced that 131I‐CIGB‐552 peptide was actually accumulated in the tumors after administration by subcutaneous route. A typical serine‐proteases degradation pattern for CIGB‐552 in BALB/c mice serum was identified. Further, biological characterization of the main metabolites of the peptide CIGB‐552 suggests that the cell‐penetrating capacity plays an important role in the cytotoxic activity. This report is the first in describing the antitumor effect induced by systemic administration of a peptide that targets COMMD1 for stabilization. Moreover, our data reinforce the perspectives of CIGB‐552 for cancer targeted therapy. Copyright © 2014 European Peptide Society and John Wiley & Sons, Ltd.Keywords
This publication has 29 references indexed in Scilit:
- The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer CellsJournal of Amino Acids, 2013
- The complexity of NF-κB signaling in inflammation and cancerMolecular Cancer, 2013
- Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted miceJournal of Theoretical Biology, 2012
- COMMD1 disrupts HIF-1α/β dimerization and inhibits human tumor cell invasionJournal of Clinical Investigation, 2010
- Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer CellsMolecular Cancer Research, 2010
- COMMD1 Promotes pVHL and O2-Independent Proteolysis of HIF-1α via HSP90/70PLOS ONE, 2009
- The Nuclear Factor-κB Pathway Controls the Progression of Prostate Cancer to Androgen-Independent GrowthCancer Research, 2008
- Studies on anticancer activities of antimicrobial peptidesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2008
- COMMD1 promotes the ubiquitination of NF‐κB subunits through a cullin‐containing ubiquitin ligaseThe EMBO Journal, 2006
- Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acidsInternational Journal of Peptide and Protein Research, 1990